Evaluation the role of CD34 in patients with acute myeloid leukemia
| Autor: | Hind Salih Muhammid, Alaa Jawad Hassan, Hussein Naji Abdulla |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | International journal of health sciences. :11677-11691 |
| ISSN: | 2550-696X 2550-6978 |
| DOI: | 10.53730/ijhs.v6ns6.13297 |
| Popis: | Acute myeloid leukemia (AML) is the most common leukemia among the adult population and accounts for about 80% of all cases, and its characterized by clonal expansion of immature “blast cells” in the peripheral blood and bone marrow .The stem cell marker CD34 is expressed by leukemia blasts only for a subset of patients with acute myelogenous leukemia (AML).The aim of this study is to determine the role of CD34 in AML and its relationship with the parameters of complete blood (CBC). A total of (60) venous blood sample from patients and (30) control their ages ranged between 18 and 66 years, The samples was collected from Baghdad medical city hospital. Sera from all participants were tested to assessment CD34 level by ELISA.In the current study, CD34 in patients and control groups show a significant difference in relation with AML patients at p-value (< 0.001). The levels of CD34 in the patients were 0.55 ± 0.03, whereas it’s significantly increased to 0.81 ± 0.05 in the control. also we found The majority of patients presented with subtype M3 38.3% of total patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|